Bacillus coagulans MTCC 5856 and Reduced Gastrointestinal Symptom Rating Scale Score

Doses used in studies

spores/day: 2 billion (median 2 billion, IQR 2 billion–2 billion) — 1 study

Safety in these studies

Overall tolerabilityReported
No adverse events or significant changes were observed in clinical parameters throughout the trial period.
from: The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A ra

1 of 1 paper

The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study

2023-03-03
RCT · n = 70
Medicine 102(9)
- M. Majeed
- K. Nagabhushanam
- Shaji Paulose
- S. Arumugam
- Lakshmi A Mundkur

PubMed: 36862903
DOI: 10.1097/MD.0000000000033109

14 Insights on

Reduced Gastrointestinal Symptom Rating Scale Score

High evidence

The cumulative GSRS score, excluding the indigestion subscale, decreased from 27.82 to 4.42% (P < .001) in the probiotic group and 29.12 to 19.33% (P < .001) in the placebo group.

Effect: Beneficial
Effect size: Large
Significant: Yes
Dose: 2 billion spores/day